Moreover, the treatment of metastatic melanoma has advanced little in the last three decades, with ipilimumab (a monoclonal antibody targeting CTLA-4 on T cells) and the BRAF inhibitor, vemurafenib, the only treatments to show an increase in overall survival and an extension of survival time, respectively. The gene discussed is CTLA4; the disease is metastatic melanoma.